Metabolic Alterations in Patients with Pheochromocytoma

Zoran Erlic; Felix Beuschlein

doi:10.1055/a-0649-0960

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2019; 127(02/03): 129-136
DOI: 10.1055/a-0649-0960

Review

Metabolic Alterations in Patients with Pheochromocytoma

Authors

Zoran Erlic

¹Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland
Felix Beuschlein

¹Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland

²Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany

Abstract

Metabolic alterations in patients with hormonally active pheochromocytoma/paraganglioma (PPGL) have been described early on in the literature. The initial findings were related to disturbed glucose homeostasis and lipolysis activation, as well as elevated metabolic rates in affected patients. Similarly, from early autopsy reports, the presence of brown adipose tissue had been noted in PPGL patients. In more recent years, changes in body weight, fat mass and distribution have been analyzed in more detail in addition to activity of brown adipose tissue based on functional imaging techniques. Over the last decades, several larger case series and cohort studies have contributed towards the elucidation of possible mechanism contributing to these clinical observations. Herein, we summarize the clinical and experimental data regarding metabolic alterations and related clinical manifestations in PPGL patients.

Key words

pheochromocytoma - catecholamine - lipid metabolism - glucose metabolism - adipose tissue - bone disease

Volltext

Referenzen

References
1 Lenders JW, Duh QY, Eisenhofer G. et al Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 1915-1942
2 Lenders JWM, Eisenhofer G, Mannelli M. et al Phaeochromocytoma. Lancet 2005; 366: 665-675
3 Mesmar B, Poola-Kella S, Malek R. The physiology behind diabetes mellitus in patients with pheochromocytoma: A review of the literature. Endocr Pract 2017; 23: 999-1005
4 Duncan LE, Semans JH, Howard JE. Adrenal medullary tumor (pheochromocytoma) and diabetes mellitus, disappearance of diabetes after removal of the tumor. Ann Intern Med 1944; 20: 815-821
5 McCullagh EP, Engel WJ. Pheochromocytoma with Hypermetabolism: Report of Two Cases. Ann Surg 1942; 116: 61-75
6 Stenstrom G, Sjostrom L, Smith U. Diabetes-Mellitus in Pheochromocytoma - Fasting Blood-Glucose Levels before and after Surgery in 60 Patients with Pheochromocytoma. Acta Endocrinol-Cop 1984; 106: 511-515
7 Beninato T, Kluijfhout WP, Drake FT. et al. Resection of Pheochromocytoma Improves Diabetes Mellitus in the Majority of Patients. Ann Surg Oncol 2017; 24: 1208-1213
8 Pogorzelski R, Toutounchi S, Krajewska E. et al The effect of surgical treatment of phaeochromocytoma on concomitant arterial hypertension and diabetes mellitus in a single-centre retrospective study. Cent European J Urol 2014; 67: 361-365
9 La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 2003; 21: 1703-1707
10 Elenkova A, Matrozova J, Zacharieva S. et al. Adiponectin - A possible factor in the pathogenesis of carbohydrate metabolism disturbances in patients with pheochromocytoma. Cytokine 2010; 50: 306-310
11 Amar L, Servais A, Gimenez-Roqueplo AP. et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocr Metab 2005; 90: 2110-2116
12 Isobe K, Fu L, Tatsuno I. et al. Adiponectin and adiponectin receptors in human pheochromocytoma. J Atheroscler Thromb 2009; 16: 442-447
13 Spyroglou A, Adolf C, Hahner S. et al. Changes in body mass index in pheochromocytoma patients following adrenalectomy. Horm Metab Res 2017; 49: 208-213
14 Petrak O, Haluzikova D, Kavalkova P. et al Changes in energy metabolism in pheochromocytoma. J Clin Endocrinol Metab 2013; 98: 1651-1658 doi: 10.1210/jc.2012-3625
15 Chen YF, Hodin RA, Pandolfi C. et al. Hypoglycemia after resection of pheochromocytoma. Surgery 2014; 156: 1404-1409
16 Modlin IM, Farndon JR, Shepherd A. et al. Phaeochromocytomas in 72 patients: Clinical and diagnostic features, treatment and long term results. Br J Surg 1979; 66: 456-465
17 Lee H, Dominiczak AF, Jennings GLR. et al. Case of chronic indolent pheochromocytoma that caused medically controlled hypertension but treatment-resistant diabetes mellitus. Hypertension 2017; 69: 740-746
18 Erlic Z, Roost K, Tschopp O. et al. Improvement of insulin secretion and oral glucose tolerance after pheochromocytoma removal: A case report. Endocrine Abstracts 2017;
19 Sedhai YR, Reddy K, Patel D et al. Unusual case of pheochromocytoma presenting with diabetic ketoacidosis. BMJ Case Rep 2016; 2016:
20 Hirai H, Midorikawa S, Suzuki S. et al. Somatostatin-secreting Pheochromocytoma Mimicking Insulin-dependent Diabetes Mellitus. Intern Med 2016; 55: 2985-2991
21 Lee IS, Lee TW, Chang CJ. et al. Pheochromocytoma presenting as hyperglycemic hyperosmolar syndrome and unusual fever. Intern Emerg Med 2015; 10: 753-755
22 Donckier JE, Rosiere A, Heureux F. et al. Diabetes mellitus as a primary manifestation of multiple endocrine neoplasia type 2B. Acta Chir Belg 2008; 108: 732-737
23 Isotani H, Fujimura Y, Furukawa K. et al. Diabetic ketoacidosis associated with the pheochromocytoma of youth. Diabetes Res Clin Pr 1996; 34: 57-60
24 Edelman ER, Stuenkel CA, Rutherford JD. et al. Diabetic-Ketoacidosis Associated with Pheochromocytoma. Clev Clin J Med 1992; 59: 423-427
25 Ishii C, Inoue K, Negishi K. et al. Diabetic ketoacidosis in a case of pheochromocytoma. Diabetes Res Clin Pr 2001; 54: 137-142
26 Tong C, England P, De Crespigny PC. et al. Diabetes mellitus as the only manifestation of occult phaeochromocytoma prior to acute haemorrhage in pregnancy. Aust Nz J Obstet Gyn 2005; 45: 91-92
27 Yamashita S, Dohi Y, Kinoshita M. et al. Occult extraadrenal pheochromocytoma treated as diabetes mellitus. Am J Med Sci 1997; 314: 276-278
28 Wilber JF, Turtle JR, Crane NA. Inhibition of Insulin Secretion by a Phaeochromocytoma. Lancet 1966; 2: 733
29 Spergel G, Bleicher SJ, Ertel NH. Carbohydrate and Fat Metabolism in Patients with Pheochromocytoma. New Engl J Med 1968; 278: 803
30 Brooks MH, Guha A, Danforth E. et al. Pheochromocytoma - Observations on Mechanism of Carbohydrate Intolerance and Abnormalities Associated with Development of Goldblatt Kidney Following Removal of Tumor. Metabolis 1969; 18: 445
31 Vance JE, Buchanan KD, Ohara D. et al. Insulin and Glucagon Responses in Subjects with Pheochromocytoma - Effect of Alpha Adrenergic Blockade. J Clin Endocr Metab 1969; 29: 911
32 Colwell JA. Inhibition of Insulin Secretion by Catecholamines in Pheochromocytoma. Ann Intern Med 1969; 71: 251
33 Hamaji M. Pancreatic Alpha-Cell and Beta-Cell Function in Pheochromocytoma. J Clin Endocr Metab 1979; 49: 322-325
34 Turnbull DM, Johnston DG, Alberti KGMM. et al Hormonal and Metabolic Studies in a Patient with a Pheochromocytoma. J Clin Endocr Metab 1980; 51: 930-933
35 Diamanti-Kandarakis E, Zapanti E, Peridis MH. et al. Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. Hormones (Athens) 2003; 2: 61-66
36 Wiesner TD, Bluher M, Windgassen M. et al. Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. J Clin Endocrinol Metab 2003; 88: 3632-3636
37 Komada H, Hirota Y, So A. et al. Insulin Secretion and Insulin Sensitivity Before and After Surgical Treatment of Pheochromocytoma or Paraganglioma. J Clin Endocrinol Metab 2017; 102: 3400-3405
38 Gribble FM. Alpha2A-adrenergic receptors and type 2 diabetes. N Engl J Med 2010; 362: 361-362
39 Okauchi Y, Ishibashi C, Shu K. et al. Decreased Serum Adiponectin Level during Catecholamine Crisis in an Obese Patient With Pheochromocytoma. Intern Med 2017;
40 Bosanska L, Petrak O, Zelinka T. et al. The effect of pheochromocytoma treatment on subclinical inflammation and endocrine function of adipose tissue. Physiol Res 2009; 58: 319-325
41 Sakane N, Yoshida T, Mizutani T. et al. Serum leptin levels in a patient with pheochromocytoma. J Clin Endocrinol Metab 1998; 83: 1400
42 Wocial B, Ignatowska-Switalska H, Berent H. et al. Do catecholamines influence the level of plasma leptin in patients with phaeochromocytoma?. Br J Biomed Sci 2002; 59: 141-144
43 Bottner A, Eisenhofer G, Torpy DJ. et al. Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients. Metabolism 1999; 48: 543-545
44 Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993; 34: 1057-1091
45 Lafontan M, Barbe P, Galitzky J. et al. Adrenergic regulation of adipocyte metabolism. Hum Reprod 1997; 12 (Suppl. 01) 6-20
46 Engelman K, Mueller PS, Sjoerdsma A. Elevated Plasma Free Fatty Acid Concentrations in Patients with Pheochromocytoma. Changes with Therapy and Correlations with the Basal Metabolic Rate. N Engl J Med 1964; 270: 865-870
47 Krentz AJ, Hale PJ, Horrocks PM. et al. Metabolic effects of pharmacological adrenergic blockade in phaeochromocytoma. Clin Endocrinol (Oxf) 1991; 34: 139-145
48 Jocken JW, Blaak EE. Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol Behav 2008; 94: 219-230
49 Winocour PH, Masud T, Clark F. et al. Lipid and lipoprotein metabolism in familial combined hyperlipidaemia during treatment of sporadic phaeochromocytoma: A case study. Postgrad Med J 1992; 68: 371-375
50 Okamura T, Nakajima Y, Satoh T. et al. Changes in visceral and subcutaneous fat mass in patients with pheochromocytoma. Metabolism 2015; 64: 706-712
51 Pedersen SB, Bak JF, Holck P. et al. Epinephrine stimulates human muscle lipoprotein lipase activity in vivo. Metabolism 1999; 48: 461-464
52 Bartelt A, John C, Schaltenberg N. et al. Thermogenic adipocytes promote HDL turnover and reverse cholesterol transport. Nat Commun 2017; 8: 15010 doi: 10.1038/ncomms15010
53 Wang QD, Zhang M, Ning G. et al. Brown Adipose Tissue in Humans Is Activated by Elevated Plasma Catecholamines Levels and Is Inversely Related to Central Obesity. Plos One 2011; 6
54 An Y, Reimann M, Masjkur J. et al. Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. Int J Obes (Lond) 2018;
55 Bahler L, Molenaars RJ, Verberne HJ. et al. Role of the autonomic nervous system in activation of human brown adipose tissue: A review of the literature. Diabetes Metab 2015; 41: 437-445
56 Rona G. Changes in Adipose Tissue Accompanying Pheochromocytoma. Can Med Assoc J 1964; 91: 303-305
57 Hadi M, Chen CC, Whatley M. et al. Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma. J Nucl Med 2007; 48: 1077-1083
58 Yeung HW, Grewal RK, Gonen M. et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003; 44: 1789-1796
59 Paulus A, Lichtenbelt WV, Mottaghy FM. et al. Brown adipose tissue and lipid metabolism imaging. Methods 2017; 130: 105-113
60 Puar T, van Berkel A, Gotthardt M. et al. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab 2016; 101: 224-232
61 Betz MJ, Slawik M, Lidell ME. et al. Presence of brown adipocytes in retroperitoneal fat from patients with benign adrenal tumors: Relationship with outdoor temperature. J Clin Endocrinol Metab 2013; 98: 4097-4104
62 Graham S, Hammond-Jones D, Gamie Z. et al. The effect of beta-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs 2008; 17: 1281-1299
63 Veldhuis-Vlug AG, El Mahdiui M, Endert E. et al. Bone resorption is increased in pheochromocytoma patients and normalizes following adrenalectomy. J Clin Endocrinol Metab 2012; 97: E2093-E2097
64 Kim BJ, Kwak MK, Ahn SH. et al. Lower Bone Mass and Higher Bone Resorption in Pheochromocytoma: Importance of Sympathetic Activity on Human Bone. J Clin Endocrinol Metab 2017; 102: 2711-2718
65 Zelinka T, Petrak O, Turkova H. et al. High incidence of cardiovascular complications in pheochromocytoma. Hormone and Metabolic Research 2012; 44: 379-384
66 Stolk RF, Bakx C, Mulder J. et al. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines?. J Clin Endocr Metab 2013; 98: 1100-1106
67 Ratge D, Wisser H. Alpha- and beta-adrenergic receptor activity in circulating blood cells of patients with phaeochromocytoma: Effects of adrenalectomy. Acta Endocrinol (Copenh) 1986; 111: 80-88
68 Valet P, Damase-Michel C, Chamontin B. et al. Platelet alpha 2- and leucocyte beta 2-adrenoceptors in phaeochromocytoma: effect of tumour removal. Eur J Clin Invest 1988; 18: 481-485